产品
编 号：F743361
分子式：C24H32FN6O8P
分子量：582.52
分子式：C24H32FN6O8P
分子量：582.52
产品类型
规格
价格
是否有货
结构图
CAS No: 1231747-08-2
产品详情
生物活性：
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes.
体内研究：
PSI-353661 (50 mg/kg, p.o., together with 400 mg/kg of Telaprevir (HY-10235), daily for 4 weeks) is effective against human hepatocyte chimeric mice infected with HCV.Animal Model:Human hepatocyte chimeric mice infected with HCV
Dosage:50 mg/kg, together with 400 mg/kg of Telaprevir
Administration:Oral administration (p.o.)
Result:Achieved sustained eradication of the mutant virus or the end-of-treatment response.Reduced serum levels of HCV RNA.
体外研究：
PSI-353661 exhibits strong inhibition of HCV in the cell-based replicon assay, with EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons.PSI-353661 (24 h) produces high concentrations of (0.44 mM) triphosphate (TP) level in primary human hepatocytes.PSI-353661 (4 days) inhibits viral replication with EC50 and EC90 value of 0.0030 μM and 0.0085 μM for genotype 1b replicon cells.PSI-353661 (8 days) shows little cytotoxicity in Huh7, HepG2, BxPC3, and CEM cells, with IC50 more than 80 μM.PSI-353661 (8-160 nM, 2 weeks) clears HCV replicon RNA and prevents viral rebound.
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes.
体内研究：
PSI-353661 (50 mg/kg, p.o., together with 400 mg/kg of Telaprevir (HY-10235), daily for 4 weeks) is effective against human hepatocyte chimeric mice infected with HCV.Animal Model:Human hepatocyte chimeric mice infected with HCV
Dosage:50 mg/kg, together with 400 mg/kg of Telaprevir
Administration:Oral administration (p.o.)
Result:Achieved sustained eradication of the mutant virus or the end-of-treatment response.Reduced serum levels of HCV RNA.
体外研究：
PSI-353661 exhibits strong inhibition of HCV in the cell-based replicon assay, with EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons.PSI-353661 (24 h) produces high concentrations of (0.44 mM) triphosphate (TP) level in primary human hepatocytes.PSI-353661 (4 days) inhibits viral replication with EC50 and EC90 value of 0.0030 μM and 0.0085 μM for genotype 1b replicon cells.PSI-353661 (8 days) shows little cytotoxicity in Huh7, HepG2, BxPC3, and CEM cells, with IC50 more than 80 μM.PSI-353661 (8-160 nM, 2 weeks) clears HCV replicon RNA and prevents viral rebound.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备